Development of a new TLR4 agonist for the treatment of Allergic Rhinitis

Inimmune Corporation, Missoula MT

Investigators

Abstract

The goal of this project is to develop an intranasal TLR4 agonist to treat allergic rhinitis.  Such treatment has the potential to provide short-term symptom control as well as long-term disease remission via allergen dependent T and B cell memory responses.